Venlafaxine
Effexor, Venlafaxine (venlafaxine) is a small molecule pharmaceutical. Venlafaxine was first approved as Effexor on 1993-12-28. It is used to treat attention deficit disorder with hyperactivity, autistic disorder, chronic fatigue syndrome, depressive disorder, and obsessive-compulsive disorder amongst others in the USA. The pharmaceutical is active against sodium-dependent serotonin transporter and sodium-dependent noradrenaline transporter.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Effexor, Venlafaxine, Venlafaxine besylate (discontinued: Effexor, Venlafaxine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Venlafaxine hydrochloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VENLAFAXINE HYDROCHLORIDE | RVL Pharmaceuticals | N-022104 RX | 2008-05-20 | 4 products, RLD |
| EFFEXOR XR | Upjohn | N-020699 RX | 1997-10-20 | 3 products, RLD, RS |
Show 2 discontinued
Venlafaxine besylate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| VENLAFAXINE BESYLATE | Almatica Pharma | N-215429 RX | 2022-06-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| New Drug Application | 2009-10-27 | |
| effexor | New Drug Application | 2023-08-15 |
| effexor xr | ANDA | 2020-11-16 |
| venlafaxine | ANDA | 2024-10-10 |
| venlafaxine hcl | ANDA | 2022-12-22 |
| venlafaxine hcl er | ANDA | 2023-07-05 |
| venlafaxine hydrochloride | ANDA | 2024-10-30 |
| venlafaxine hydrochloride, extended release | ANDA | 2024-01-04 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
HCPCS
No data
Clinical
Clinical Trials
260 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 3 | 23 | 37 | 53 | 33 | 144 |
| Depressive disorder | D003866 | EFO_1002014 | F32.A | 4 | 23 | 38 | 46 | 26 | 132 |
| Major depressive disorder | D003865 | EFO_0003761 | F22 | 4 | 16 | 25 | 29 | 17 | 87 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | 4 | 6 | 5 | 5 | 19 |
| Healthy volunteers/patients | — | — | — | 14 | — | 1 | 1 | 1 | 17 |
| Treatment-resistant depressive disorder | D061218 | — | — | — | — | 7 | 3 | 2 | 12 |
| Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | 1 | 2 | 5 | 1 | 9 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | — | — | — | 4 | 3 | 7 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | 2 | 4 | 6 |
| Mood disorders | D019964 | EFO_0004247 | F30-F39 | — | — | 1 | 2 | 2 | 5 |
Show 39 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hot flashes | D019584 | — | — | — | 2 | 3 | — | 5 | 10 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 2 | — | 2 | 5 |
| Obsessive-compulsive disorder | D009771 | EFO_0004242 | F42 | — | 1 | 1 | — | 2 | 4 |
| Compulsive personality disorder | D003193 | — | F60.5 | — | 1 | 1 | — | 1 | 3 |
| Mental disorders | D001523 | EFO_0000677 | F91.9 | — | — | 1 | — | 1 | 2 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | — | — | 2 | — | — | 2 |
| Cancer pain | D000072716 | — | G89.3 | — | 1 | 1 | — | 1 | 2 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | 1 | 1 | — | 1 | 2 |
| Alcohol-related disorders | D019973 | — | F10 | — | 1 | 1 | — | 1 | 2 |
| Attempted suicide | D013406 | EFO_0004321 | T14.91 | — | 1 | 1 | — | 1 | 2 |
Show 10 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Suicidal ideation | D059020 | EFO_0004320 | R45.851 | — | 1 | — | — | 1 | 2 |
| Myofascial pain syndromes | D009209 | EFO_1001054 | — | 1 | 1 | — | — | — | 1 |
| Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 1 | — | — | — | 1 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | — | 1 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | — | 1 | — | — | — | 1 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | — | 1 | — | — | — | 1 |
| Insulin resistance | D007333 | HP_0000855 | — | — | 1 | — | — | — | 1 |
| Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | 1 | — | — | — | 1 |
| Post-head injury coma | D020207 | — | — | — | 1 | — | — | — | 1 |
| Neck pain | D019547 | HP_0030833 | M54.2 | — | 1 | — | — | — | 1 |
Show 4 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | 4 | — | — | — | — | 4 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | 1 | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | — | — | — | 1 | 2 |
| Bariatric surgery | D050110 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | — | 5 | 5 |
| Neoplasms | D009369 | — | C80 | — | — | — | — | 2 | 2 |
| Intractable pain | D010148 | — | — | — | — | — | — | 1 | 1 |
| Pharmacokinetics | D010599 | — | — | — | — | — | — | 1 | 1 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
| Inflammation | D007249 | MP_0001845 | — | — | — | — | — | 1 | 1 |
| Substance-related disorders | D019966 | EFO_0003890 | F13 | — | — | — | — | 1 | 1 |
| Chronic disease | D002908 | — | — | — | — | — | — | 1 | 1 |
| Acute kidney injury | D058186 | HP_0001919 | N17 | — | — | — | — | 1 | 1 |
| Carcinoma | D002277 | — | C80.0 | — | — | — | — | 1 | 1 |
Show 23 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Venlafaxine |
| INN | venlafaxine |
| Description | Venlafaxine is a tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group. It has a role as an antidepressant, a serotonin uptake inhibitor, an adrenergic uptake inhibitor, a dopamine uptake inhibitor, an analgesic, an environmental contaminant and a xenobiotic. It is a member of cyclohexanols, a tertiary alcohol, a tertiary amino compound and a monomethoxybenzene. |
| Classification | Small molecule |
| Drug class | antianxiety, antidepressant inhibitor of norepinephrine and dopamine re-uptake |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(C(CN(C)C)C2(O)CCCCC2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 93413-69-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL637 |
| ChEBI ID | 9943 |
| PubChem CID | 5656 |
| DrugBank | DB00285 |
| UNII ID | GRZ5RCB1QG (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Estimated US medical usage
Venlafaxine
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 17,593 documents
View more details
Safety
Black-box Warning
Black-box warning for: Effexor, Venlafaxine hcl, Venlafaxine hydrochloride, Venlafaxine hydrochloride, extended release
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
78,604 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use